Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Erlotinib with Pemetrexed/Carboplatin in EGFR-mutated NSCLC
NCT02066038Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02066038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066038.